What is UroGen Pharma Ltd (URGN) stock price today?

UroGen Pharma Ltd (URGN) currently trades at $23.83 per share. The stock has a market capitalization of $1.14B and a P/E ratio of —x.

Is URGN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, UroGen Pharma Ltd has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -4.19.

What is UroGen Pharma Ltd's revenue and earnings?

UroGen Pharma Ltd has trailing twelve-month (TTM) revenue of $109.79M with profit margins of -139.80%. Earnings per share (EPS) is $-3.19.

Is UroGen Pharma Ltd financially healthy?

UroGen Pharma Ltd's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -4.19 places it in the distress.

URGN

UroGen Pharma Ltd

NASDAQ: URGN · HEALTHCARE · BIOTECHNOLOGY

$23.83

+2.10% today

Updated 2026-04-30

Market cap

$1.14B

P/E ratio

—

P/S ratio

10.35x

EPS (TTM)

$-3.19

Dividend yield

—

52W range

$3 – $30

Volume

0.8M

Market cap

$1.14B

P/E ratio

—

P/S ratio

10.35x

EPS (TTM)

$-3.19

Dividend yield

—

52W range

$3 – $30

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

6.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-4.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$33.88

+42.17%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 54.00% QoQ

+ Debt/equity -1.13x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -4.19 — distress zone

- Thin margins at -139.80%

- Negative free cash flow $-38.34M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$64.36M	$82.71M	$90.40M	$109.79M	$109.79M
Net income	$-109.78M	$-102.24M	$-126.87M	$-153.49M	$-26.36M
EPS	—	—	—	—	$-3.19
Free cash flow	$-87.81M	$-76.57M	$-97.06M	$-162.73M	$-38.34M
Profit margin	-170.58%	-123.61%	-140.35%	-139.81%	-139.80%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
URGN	$1.14B	28	7.3	2.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

UroGen Pharma Ltd trades at $23.83. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -4.19, it sits in the distress. TTM revenue stands at $109.79M. with profit margins at -139.80%.

Frequently asked questions

What is UroGen Pharma Ltd's stock price?

UroGen Pharma Ltd (URGN) trades at $23.83.

Is UroGen Pharma Ltd overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of UroGen Pharma Ltd (URGN)?

The analyst target price is $33.88, representing +42.2% upside from the current price of $23.83.

What is UroGen Pharma Ltd's revenue?

TTM revenue is $109.79M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-4.19 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio10.35x

ROE-1,481.00%

Beta1.44

50D MA$20.34

200D MA$20.37

Shares out0.05B

Float0.04B

Short ratio—

Avg volume0.8M

Performance

1 week-0.28%

1 month+16.40%

3 months+14.41%

YTD-8.16%

1 year—

3 years—

5 years—

Compare

URGN vs LLY →URGN vs JNJ →URGN vs ABBV →Stock screener →